Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J.

J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4.

PMID:
20921465
2.

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Tol J, Punt CJ.

Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012. Review.

PMID:
20399983
3.

Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer.

Wang L, Chen X, Li W, Sheng Z.

Anticancer Drugs. 2012 Feb;23(2):155-60. doi: 10.1097/CAD.0b013e32834c3256. Review.

PMID:
21955998
4.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

García-Foncillas J, Díaz-Rubio E.

Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3. Review.

PMID:
20709651
5.

Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.

Song QB, Wang Q, Hu WG.

World J Gastroenterol. 2015 Apr 14;21(14):4365-72. doi: 10.3748/wjg.v21.i14.4365. Review.

6.

Spotlight on panitumumab in metastatic colorectal cancer.

Keating GM.

BioDrugs. 2010 Aug 1;24(4):275-8. doi: 10.2165/11205460-000000000-00000. Review.

PMID:
20623992
7.

Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.

Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, Xu JM.

World J Gastroenterol. 2014 Apr 21;20(15):4263-75. doi: 10.3748/wjg.v20.i15.4263. Review.

8.

Integration of panitumumab into the treatment of colorectal cancer.

Gravalos C, Cassinello J, García-Alfonso P, Jimeno A.

Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26. doi: 10.1016/j.critrevonc.2009.06.005. Epub 2009 Jul 17. Review.

PMID:
19616446
9.

Panitumumab: a review of its use in metastatic colorectal cancer.

Keating GM.

Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000. Review.

PMID:
20481659
10.

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.

Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL.

Int J Cancer. 2013 Oct 15;133(8):1914-25. doi: 10.1002/ijc.28153. Epub 2013 Jul 13. Review. Erratum in: Int J Cancer. 2014 Jul 15;135(2):E2.

11.

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS.

Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Epub 2014 Aug 12. Review.

PMID:
25115304
12.

Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma.

Peeters M, Cohn A, Köhne CH, Douillard JY.

Clin Colorectal Cancer. 2012 Mar;11(1):14-23. doi: 10.1016/j.clcc.2011.06.010. Epub 2011 Sep 16. Review.

PMID:
21925954
13.

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Yang ZY, Hu XF, Chen Q, Tang JL.

Ann Oncol. 2012 Jun;23(6):1518-25. doi: 10.1093/annonc/mdr464. Epub 2011 Oct 29. Review.

PMID:
22039088
14.

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.

Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA.

Ann Intern Med. 2011 Jan 4;154(1):37-49. doi: 10.7326/0003-4819-154-1-201101040-00006. Review.

PMID:
21200037
15.
16.

Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis.

Lin AY, Buckley NS, Lu AT, Kouzminova NB, Salpeter SR.

Clin Colorectal Cancer. 2011 Mar 1;10(1):63-9. doi: 10.3816/CCC.2011.n.009. Review.

PMID:
21609938
17.

Role of cetuximab in first-line treatment of metastatic colorectal cancer.

Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E.

World J Gastroenterol. 2014 Apr 21;20(15):4208-19. doi: 10.3748/wjg.v20.i15.4208. Review.

18.

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. Review.

19.

Cetuximab in the treatment of patients with colorectal cancer.

Garrett CR, Eng C.

Expert Opin Biol Ther. 2011 Jul;11(7):937-49. doi: 10.1517/14712598.2011.582464. Epub 2011 May 11. Review.

PMID:
21557708
20.

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.

Li W, Shi Q, Wang W, Liu J, Ren J, Li Q, Hou F.

Colorectal Dis. 2014 Nov;16(11):O370-8. doi: 10.1111/codi.12749. Review.

PMID:
25155261

Supplemental Content

Support Center